Reduced expression of somatostatin in GABAergic interneurons derived from induced pluripotent stem cells of patients with parkin mutations

[1]  P. Sachdev,et al.  Differential expression of synaptic and interneuron genes in the aging human prefrontal cortex , 2018, Neurobiology of Aging.

[2]  B. Czéh,et al.  Long-Term Stress Disrupts the Structural and Functional Integrity of GABAergic Neuronal Networks in the Medial Prefrontal Cortex of Rats , 2018, Front. Cell. Neurosci..

[3]  H. Okano,et al.  Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction , 2018, Molecular Brain.

[4]  H. Okano,et al.  Escape from Pluripotency via Inhibition of TGF-β/BMP and Activation of Wnt Signaling Accelerates Differentiation and Aging in hPSC Progeny Cells , 2017, Stem cell reports.

[5]  A. Miyawaki,et al.  Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons. , 2017, Biochemical and biophysical research communications.

[6]  M. Kossut,et al.  Somatostatin and Somatostatin-Containing Neurons in Shaping Neuronal Activity and Plasticity , 2016, Front. Neural Circuits.

[7]  J. Błaszczyk.  Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis , 2016, Front. Neurosci..

[8]  H. Okano,et al.  Functional Neurons Generated from T Cell-Derived Induced Pluripotent Stem Cells for Neurological Disease Modeling , 2016, Stem Cell Reports.

[9]  Robert Krencik,et al.  Efficient generation of region-specific forebrain neurons from human pluripotent stem cells under highly defined condition , 2015, Scientific Reports.

[10]  H. Okano,et al.  Controlling the Regional Identity of hPSC-Derived Neurons to Uncover Neuronal Subtype Specificity of Neurological Disease Phenotypes , 2015, Stem cell reports.

[11]  Xiaoguang Luo,et al.  Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia , 2015, Molecular medicine reports.

[12]  Hongbin Sun,et al.  Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson’s disease , 2015, Journal of Neural Transmission.

[13]  Irina I. Pushinskaya,et al.  Somatostatin antagonist induces catalepsy in the aged rat , 2013, Psychopharmacology.

[14]  H. Okano,et al.  Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue , 2012, Molecular Brain.

[15]  L. Gentet.  Functional diversity of supragranular GABAergic neurons in the barrel cortex , 2012, Front. Neural Circuits.

[16]  G. Du,et al.  Assessment of the treatment effect of baicalein on a model of Parkinsonian tremor and elucidation of the mechanism. , 2012, Life sciences.

[17]  Zhen Yan,et al.  Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells , 2012, Nature Communications.

[18]  D. Hoyer,et al.  Somatostatin, Alzheimer's disease and cognition: An old story coming of age? , 2009, Progress in Neurobiology.

[19]  Lawrence Lum,et al.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.

[20]  E. P. Gardner,et al.  Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex , 2008, Nature Reviews Neuroscience.

[21]  A. Simon,et al.  Somatostatinergic systems in brain: Networks and functions , 2008, Molecular and Cellular Endocrinology.

[22]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[23]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[24]  S. Anderson,et al.  The origin and specification of cortical interneurons , 2006, Nature Reviews Neuroscience.

[25]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[26]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[27]  E. van Cauter,et al.  Physiological role of somatostatin on growth hormone regulation in humans. , 1990, Metabolism: clinical and experimental.

[28]  C. Beglinger,et al.  A physiologic role for somatostatin 28 as a regulator of insulin secretion. , 1989, The Journal of clinical investigation.

[29]  Y. Agid,et al.  Somatostatin and dementia in Parkinson's disease , 1983, Brain Research.

[30]  B. Manyam.  Low CSF γ-Aminobutyric Acid Levels in Parkinson's Disease: Effect of Levodopa and Carbidopa , 1982 .

[31]  A. P. Hansen,et al.  Low cerebrospinal fluid somatostatin in Parkinson disease , 1982, Neurology.

[32]  C. Baumann,et al.  Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease , 2018, Front. Neurol..

[33]  B. Thiers.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[34]  G. Hamann,et al.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease — effect of L-Dopa , 2005, Journal of Neural Transmission.

[35]  B. Manyam.  Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa. , 1982, Archives of neurology.